(Q38040846)

English

Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma

scientific article published on October 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Sheridan M Hoy

1

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

publication date

1 October 2012

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

72

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

1929-1950

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Bendamustine: rebirth of an old drug

1 reference

https://api.crossref.org/works/10.2165%2F11209510-000000000-00000

21 January 2018

Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.2165%2F11209510-000000000-00000

21 January 2018

Bendamustine: a review of its use in the management of indolent non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.2165%2F11209510-000000000-00000

21 January 2018

Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.2165%2F11209510-000000000-00000

21 January 2018

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

1 reference

https://api.crossref.org/works/10.2165%2F11209510-000000000-00000

21 January 2018

Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity

1 reference

https://api.crossref.org/works/10.2165%2F11209510-000000000-00000

21 January 2018

Bendamustine: rescue of an effective antineoplastic agent from the mid-twentieth century

1 reference

https://api.crossref.org/works/10.2165%2F11209510-000000000-00000

21 January 2018

Dose dependent effects on cell cycle checkpoints and DNA repair by bendamustine

1 reference

https://api.crossref.org/works/10.2165%2F11209510-000000000-00000

21 January 2018

Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling

1 reference

https://api.crossref.org/works/10.2165%2F11209510-000000000-00000

21 January 2018

Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride

1 reference

https://api.crossref.org/works/10.2165%2F11209510-000000000-00000

21 January 2018

Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.2165%2F11209510-000000000-00000

21 January 2018

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.2165%2F11209510-000000000-00000

21 January 2018

Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis

1 reference

https://api.crossref.org/works/10.2165%2F11209510-000000000-00000

21 January 2018

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study

1 reference

https://api.crossref.org/works/10.2165%2F11209510-000000000-00000

21 January 2018

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.2165%2F11209510-000000000-00000

21 January 2018

Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and predniso

1 reference

https://api.crossref.org/works/10.2165%2F11209510-000000000-00000

21 January 2018

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

https://api.crossref.org/works/10.2165%2F11209510-000000000-00000

21 January 2018

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.2165%2F11209510-000000000-00000

21 January 2018

Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy

1 reference

https://api.crossref.org/works/10.2165%2F11209510-000000000-00000

21 January 2018

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.2165%2F11209510-000000000-00000

21 January 2018

Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel

1 reference

https://api.crossref.org/works/10.2165%2F11209510-000000000-00000

21 January 2018

Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/22950536

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/22950536

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22950536

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination chemotherapy for multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22950536

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22950536

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22950536

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/22950536

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/22950536

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of clinical, laboratory, and histological characteristics in multiple myeloma: improved definition of risk groups

1 reference

https://pubmed.ncbi.nlm.nih.gov/22950536

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22950536

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bendamustine induced neurotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/22950536

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11209510-000000000-00000

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38040846&oldid=2201201825"